268 related articles for article (PubMed ID: 27475883)
1. Targeting the transsulfuration-H2S pathway by FXR and GPBAR1 ligands in the treatment of portal hypertension.
Fiorucci S; Distrutti E
Pharmacol Res; 2016 Sep; 111():749-756. PubMed ID: 27475883
[TBL] [Abstract][Full Text] [Related]
2. Reversal of Endothelial Dysfunction by GPBAR1 Agonism in Portal Hypertension Involves a AKT/FOXOA1 Dependent Regulation of H2S Generation and Endothelin-1.
Renga B; Cipriani S; Carino A; Simonetti M; Zampella A; Fiorucci S
PLoS One; 2015; 10(11):e0141082. PubMed ID: 26539823
[TBL] [Abstract][Full Text] [Related]
3. Decoding the vasoregulatory activities of bile acid-activated receptors in systemic and portal circulation: role of gaseous mediators.
Fiorucci S; Zampella A; Cirino G; Bucci M; Distrutti E
Am J Physiol Heart Circ Physiol; 2017 Jan; 312(1):H21-H32. PubMed ID: 27765751
[TBL] [Abstract][Full Text] [Related]
4. Cystathionine γ-lyase, a H2S-generating enzyme, is a GPBAR1-regulated gene and contributes to vasodilation caused by secondary bile acids.
Renga B; Bucci M; Cipriani S; Carino A; Monti MC; Zampella A; Gargiulo A; d'Emmanuele di Villa Bianca R; Distrutti E; Fiorucci S
Am J Physiol Heart Circ Physiol; 2015 Jul; 309(1):H114-26. PubMed ID: 25934094
[TBL] [Abstract][Full Text] [Related]
5. Bile-acid-activated farnesoid X receptor regulates hydrogen sulfide production and hepatic microcirculation.
Renga B; Mencarelli A; Migliorati M; Distrutti E; Fiorucci S
World J Gastroenterol; 2009 May; 15(17):2097-108. PubMed ID: 19418582
[TBL] [Abstract][Full Text] [Related]
6. Bile Acids and Portal Hypertension.
Arab JP; Barrera F; Arrese M
Ann Hepatol; 2017 Nov; 16(Suppl. 1: s3-105.):s83-s86. PubMed ID: 29080345
[TBL] [Abstract][Full Text] [Related]
7. The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction.
Schwabl P; Hambruch E; Seeland BA; Hayden H; Wagner M; Garnys L; Strobel B; Schubert TL; Riedl F; Mitteregger D; Burnet M; Starlinger P; Oberhuber G; Deuschle U; Rohr-Udilova N; Podesser BK; Peck-Radosavljevic M; Reiberger T; Kremoser C; Trauner M
J Hepatol; 2017 Apr; 66(4):724-733. PubMed ID: 27993716
[TBL] [Abstract][Full Text] [Related]
8. Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats.
Verbeke L; Farre R; Trebicka J; Komuta M; Roskams T; Klein S; Elst IV; Windmolders P; Vanuytsel T; Nevens F; Laleman W
Hepatology; 2014 Jun; 59(6):2286-98. PubMed ID: 24259407
[TBL] [Abstract][Full Text] [Related]
9. The third gas: H2S regulates perfusion pressure in both the isolated and perfused normal rat liver and in cirrhosis.
Fiorucci S; Antonelli E; Mencarelli A; Orlandi S; Renga B; Rizzo G; Distrutti E; Shah V; Morelli A
Hepatology; 2005 Sep; 42(3):539-48. PubMed ID: 16108046
[TBL] [Abstract][Full Text] [Related]
10. Chemistry and Pharmacology of GPBAR1 and FXR Selective Agonists, Dual Agonists, and Antagonists.
De Marino S; Festa C; Sepe V; Zampella A
Handb Exp Pharmacol; 2019; 256():137-165. PubMed ID: 31201554
[TBL] [Abstract][Full Text] [Related]
11. Changes in hydrogen sulfide in rats with hepatic cirrhosis in different stages.
Zhang N; Zheng Y; Chen WG; Li R; Song LX; Xu LH; Xu KS
J Huazhong Univ Sci Technolog Med Sci; 2017 Oct; 37(5):705-710. PubMed ID: 29058283
[TBL] [Abstract][Full Text] [Related]
12. Pathophysiology and a Rational Basis of Therapy.
Gracia-Sancho J; Maeso-Díaz R; Bosch J
Dig Dis; 2015; 33(4):508-14. PubMed ID: 26159267
[TBL] [Abstract][Full Text] [Related]
13. Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats.
Laleman W; Van Landeghem L; Van der Elst I; Zeegers M; Fevery J; Nevens F
Gastroenterology; 2007 Feb; 132(2):709-19. PubMed ID: 17258737
[TBL] [Abstract][Full Text] [Related]
14. Disruption of TFGβ-SMAD3 pathway by the nuclear receptor SHP mediates the antifibrotic activities of BAR704, a novel highly selective FXR ligand.
Carino A; Biagioli M; Marchianò S; Scarpelli P; Zampella A; Limongelli V; Fiorucci S
Pharmacol Res; 2018 May; 131():17-31. PubMed ID: 29530598
[TBL] [Abstract][Full Text] [Related]
15. Protective effects of hydrogen sulfide on portal hypertensive vasculopathy in rabbits by activating AKT-NF-κB pathway.
Wang C; Han J; Li DJ; Yang Z; Zhang L
J Huazhong Univ Sci Technolog Med Sci; 2017 Jun; 37(3):348-351. PubMed ID: 28585141
[TBL] [Abstract][Full Text] [Related]
16. Involvement of hydrogen sulfide and homocysteine transsulfuration pathway in the progression of kidney fibrosis after ureteral obstruction.
Jung KJ; Jang HS; Kim JI; Han SJ; Park JW; Park KM
Biochim Biophys Acta; 2013 Dec; 1832(12):1989-97. PubMed ID: 23846016
[TBL] [Abstract][Full Text] [Related]
17. Resveratrol improves intrahepatic endothelial dysfunction and reduces hepatic fibrosis and portal pressure in cirrhotic rats.
Di Pascoli M; Diví M; Rodríguez-Vilarrupla A; Rosado E; Gracia-Sancho J; Vilaseca M; Bosch J; García-Pagán JC
J Hepatol; 2013 May; 58(5):904-10. PubMed ID: 23262250
[TBL] [Abstract][Full Text] [Related]
18. Current concepts on the role of nitric oxide in portal hypertension.
Hu LS; George J; Wang JH
World J Gastroenterol; 2013 Mar; 19(11):1707-17. PubMed ID: 23555159
[TBL] [Abstract][Full Text] [Related]
19. Identification of an Oleanane-Type Triterpene Hedragonic Acid as a Novel Farnesoid X Receptor Ligand with Liver Protective Effects and Anti-inflammatory Activity.
Lu Y; Zheng W; Lin S; Guo F; Zhu Y; Wei Y; Liu X; Jin S; Jin L; Li Y
Mol Pharmacol; 2018 Feb; 93(2):63-72. PubMed ID: 29162643
[TBL] [Abstract][Full Text] [Related]
20. Thalidomide ameliorates portal hypertension via nitric oxide synthase independent reduced systolic blood pressure.
Theodorakis NG; Wang YN; Korshunov VA; Maluccio MA; Skill NJ
World J Gastroenterol; 2015 Apr; 21(14):4126-35. PubMed ID: 25892862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
